NHS Doctors Unveil Comprehensive Blueprint for Safe AI Integration in Healthcare

The National Commission into the Regulation of AI in Healthcare has released its recommendations today, 10 September 2026, outlining how the UK can enhance the regulation of artificial intelligence within the healthcare sector, ensuring safety, fostering innovation, and maintaining public trust.

AI technology is already employed within the NHS to identify critical health issues at an early stage, such as strokes and skin cancers, while also utilising voice-enabled technologies to alleviate clinicians’ workloads. The Commission’s proposals aim to facilitate a broader, safe, and swift integration of AI, positioning the UK as the premier destination for innovators to develop and test AI solutions, healthcare professionals to implement them, and patients to engage positively with these advancements in their care.

Envisioning the Future of AI in Healthcare

In the introduction of this report, Professors Alastair Denniston and Henrietta Hughes, both serving NHS doctors, remarked:

“The National Commission into the Regulation of AI in Healthcare seeks to define our aspirations for a future healthcare system enriched by AI and how regulation can shape this vision. We aim to create a healthcare environment that is increasingly technology-driven while remaining focused on patient needs.”

Lawrence Tallon, Chief Executive of the MHRA, expressed his support for the comprehensive and independent recommendations. He articulated:

“This report provides unprecedented detail on how we should regulate AI in healthcare effectively.

“The potential of AI to accelerate and enhance patient care, allowing clinicians to dedicate more time to the human aspects of their roles, is evident. However, these opportunities can only be realised with a modern and dynamic regulatory framework that facilitates safe adoption, protects patients, and inspires confidence among the public and professionals. I extend my gratitude to all those who contributed to this expert Commission, which has laid out a clear path forward.”

A Comprehensive Engagement with Stakeholders

Established by the Medicines and Healthcare products Regulatory Agency (MHRA) in September 2025, the independent Commission comprises a diverse array of expertise in health, regulation, and AI, including international contributors from countries such as the USA and Singapore.

Over the past year, the Commission gathered insights from more than 12,000 individuals, including patients, the public, healthcare professionals, and technology developers. This extensive engagement marks the largest of its kind in the UK regarding the regulation of healthcare technologies. Additionally, in-depth research conducted by the Health Foundation, published alongside the Commission’s findings, provides critical insights into public expectations concerning AI regulation in healthcare.

Public Support for AI with Clear Conditions

The engagement revealed a significant public endorsement for AI in healthcare, contingent upon stringent safety standards, meaningful human oversight, and transparency regarding AI usage in patient care. The recommendations presented by the Commission directly address these public sentiments.

One key recommendation is for the MHRA to implement staged authorisations for new AI models, akin to ‘L-plates’ for novice drivers. This approach permits new models to be deployed under rigorous supervision and defined parameters, enabling them to showcase safety and effectiveness in real-world scenarios before receiving full authorisation. Such a staged process aims to provide UK patients with early access to innovative models while carefully managing associated risks.

Ongoing Monitoring and Transparency in AI

The Commission advocates for continuous, real-world monitoring of AI-enabled medical devices throughout their operational lifespan, rather than relying solely on a one-time approval process. This recommendation reflects the evolving nature of AI technologies post-deployment, ensuring that as these systems adapt, patient safety remains paramount and regulators can respond promptly to any emerging issues.

Moreover, the Commission calls for enhanced public access to safety information related to specific AI-enabled medical devices, including records of any adverse incidents. By building upon existing resources such as the MHRA’s interactive Drug Analysis Profiles, patients and the public will gain accessible and trustworthy information. Patients have also expressed a desire to be informed when AI is being employed in their care, and the recommendations propose a balanced approach to ensure this information is conveyed as AI becomes increasingly integrated into NHS services.

Strengthening Regulatory Powers for Patient Protection

To safeguard patient interests, the Commission recommends that the MHRA be granted enhanced enforcement powers, ensuring that decisive action can be taken when AI systems do not meet the expected standards.

The government and MHRA will now deliberate on the Commission’s recommendations, with a formal response anticipated in due course.

Building Trust Through Responsible Innovation

Professor Alastair Denniston, NHS consultant and Chair of the Commission, stated:

“We innovate because we aspire for tomorrow’s healthcare to surpass today’s. However, every new innovation, including AI, must earn its place and the trust of the public. These technologies need to demonstrate their safety and effectiveness while delivering benefits to patients, staff, and the NHS as a whole, ensuring no one is left behind. Over the past year, we have engaged with over 12,000 individuals, including patients, carers, clinicians, and AI developers. A consistent message emerged: there is openness to AI enhancing care, but only under the conditions of safety, human oversight, and patient awareness. These recommendations aim to establish that trust, positioning the UK as a leader not just in AI development for healthcare but also in its responsible regulation and utilisation.”

Professor Henrietta Hughes, NHS General Practitioner and Deputy Chair of the Commission, echoed this sentiment, stating:

“Patients have expressed that to trust AI, they need to know when it is used, that it supports clinicians rather than replaces them, and that accountability is clear should any issues arise. Our recommendations address these requirements, placing people at the forefront of technology to enhance care and allowing clinicians more time to address patient needs. This approach is vital for ensuring safety and building confidence within the health system to fully embrace AI’s potential.”

Expert Opinions on the Future of AI in Healthcare

Professor Neil Lawrence, Chair of the Technology Working Group, emphasised the unique challenges posed by generative AI, noting its variable behaviour and evolution post-deployment. He stated:

“This necessitates a departure from relying on a single approval point. Our recommendations recognise this reality and propose a pragmatic, proportionate method for overseeing AI technologies throughout their operational life. It is essential to be transparent about the uncertainties inherent in these systems, enabling patients and clinicians to discern when AI outputs are applicable and when they warrant scrutiny.”

Jennifer Dixon, Chief Executive of the Health Foundation, remarked:

“We are proud to have supported the Commission’s evidence base for this report. The public’s consistent message has been clear: they welcome a greater role for AI in their care, but this willingness is entirely contingent on trust. While the MHRA’s regulatory role is critical, the true test lies in the NHS’s capability to implement and monitor AI applications safely and effectively at the required scale.”

Additional supportive voices from the health sector echoed these sentiments, highlighting the importance of responsible innovation, public trust, and the need for clear regulatory frameworks to foster the safe integration of AI in healthcare.

Conclusion and Next Steps

The full report, along with an easy-read version and a Welsh language edition, is available from today. The Commission, established by the MHRA as an independent advisory body, aims to support the safe and efficient regulation, development, and use of AI in healthcare. Its recommendations are informed by extensive research and engagement activities, ensuring that they reflect the needs and expectations of the public and healthcare professionals alike.

As the UK seeks to navigate the complexities of AI in healthcare, these recommendations will serve as a foundation for a regulatory framework that prioritises safety, transparency, and public trust while fostering an environment conducive to innovation.